Eli Lilly Reports Results of Ultra Rapid Lispro (URLi) in Two P-III Studies for Type 1 And Type 2 Diabetes

Eli Lilly Reports Results of Ultra Rapid Lispro (URLi) in Two P-III Studies for Type 1 And Type 2 Diabetes

Shots:

  • The two P-III PRONTO-T1D & PRONTO-T2D studies result involves assessing of Ultra Rapid Lispro (URLi) vs Humalog (insulin lispro), both in combination with insulin glargine/degludec in 1,222 & 673 patients with T1D and T2D respectively
  • The P-III PRONTO-T1D & PRONTO-T2D studies resulted in meeting its 1EPs i.e, A1C reduction at mealtime @26wks., longer time in range(43.6+ mins), reduction in blood glucose spikes in both T1D and T2D followed by test meal @1hrs. & 2hrs. (-27.9 mg/dL and -11.8 mg/dL) & (-31.2 mg/dL and -17.4 mg/dL) respectively
  • URLi (SC) is a mealtime insulin formulation intended to reduce postprandial glucose with its expected approval in Europe & Japan and regulatory submission in the US in H2’19

Click here to read full press release/ article | Ref: Eli Lilly| Image: ID Works Global